CoChat

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Open access
Coates, James T., Sun, Sheng, Leshchiner, Ignaty, Thimmiah, Nayana, Martin, Elizabeth E., McLoughlin, Daniel, Danysh, Brian P., Slowik, Kara, Jacobs, Raquel A., Rhrissorrakrai, Kahn, Utro, Filippo, Levovitz, Chaya, Denault, Elyssa, Walmsley, Charlotte S., Kambadakone, Avinash, Stone, James R., Isakoff, Steven J., Parida, Laxmi, Juric, Dejan, Getz, Gad, Bardia, Aditya, Ellisen, Leif W. · 2021 · Cancer Discovery
Cited by 248

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Sacituzumab govitecan (SG), the first antibody–drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We sought to identify mechanisms of SG resistance through RNA and whole-exome sequencing of pretreatment and postprogression specimens. One patient exhibiting de novo progression lacked TROP2 expression, in contrast to robust TROP2 expression and focal genomic amplification of TACSTD2/TROP2 observed in a patient with a deep, prolonged response to SG. Analysis of acquired genomic resistance in this case revealed one phylogenetic branch harboring a canonical TOP1E418K resistance mutation and subsequent frameshift TOP1 mutation, whereas a distinct branch exhibited a novel TACSTD2/TROP2T256R missense mutation. Reconstitution experiments demonstrated that TROP2T256R confers SG resistance via defective plasma membrane localization and reduced cell-surface binding by hRS7. These findings highlight parallel genomic alterations in both antibody and payload targets associated with resistance to SG. Significance: These findings underscore TROP2 as a response determinant and reveal acquired SG resistance mechanisms involving the direct antibody and drug payload targets in distinct metastatic subclones of an individual patient. This study highlights the specificity of SG and illustrates how such mechanisms will inform therapeutic strategies to overcome ADC resistance. This article is highlighted in the In This Issue feature, p. 2355

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0702

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 248

Metadata

Authors
Coates, J. T., Sun, S., Leshchiner, I., Thimmiah, N., Martin, E. E., McLoughlin, D., Danysh, B. P., Slowik, K., Jacobs, R. A., Rhrissorrakrai, K., Utro, F., Levovitz, C., Denault, E., Walmsley, C. S., Kambadakone, A., Stone, J. R., Isakoff, S. J., Parida, L., Juric, D., Getz, G., Bardia, A., & Ellisen, L. W.
Venue
Cancer Discovery
Published
2021-08-17
Volume
11
Issue
10
Pages
2436-2445
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3196246553
Cited by
248
References
5
FWCI
8.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.